NCT06616779Completed
DigiDiab Evaluation Domiciliary Nursing Care
An Open, Single-centre, Non-interventional Study of the CE-marked Medical Device GlucoTab, According to Intended Use Without Additional Invasive and Stressful Measures
Source: ClinicalTrials.gov · Last updated 1 Aug 2025
Brief summary (registry, in English)
GlucoTab is a stand-alone software system to support healthcare professionals in the care of patients with diabetes mellitus or newly diagnosed hyperglycaemia who are treated with insulin and/or other glucose-lowering drugs or of patients only requiring glucose monitoring. It provides a therapy algorithm for subcutaneous basal insulin therapy of patients with type 2 diabetes, which will be used in this study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 19 Sept 2024
- Start date
- 30 Nov 2024
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Medical University of Graz
- Diseases
- Type 2 diabetes
- NCT number
- NCT06616779
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 30 Nov 2024 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- intravenous insulin therapy
- hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
Other illness
- type 1 diabetes mellitus
- gestational diabetes or pregnancy
- known or suspected allergy to insulin
- any mental condition rendering the patient incapable of giving his/her consent
- any disease or condition which according to the investigator would interfere with the trial or the safety of the patient
Other
- continuous subcutaneous insulin infusion
- total parenteral nutrition
Who the study is looking for
- Informed consent obtained after being advised of the nature of the study
- Male or female aged ≥ 18 years
- Type 2 diabetes (treated with insulin therapy)
- Receiving domiciliary nursing care
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Austrian Red Cross Coordinator of this site? Confirm its status | Graz | Austria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.